News Ignota vacuums up Kronos Bio's drug programmes Ignota Labs of the UK has acquired all of the clinical-stage assets in Kronos Bio's pipeline, after the US firm ceased operations earlier this year.
News Genmab agrees $8bn takeover of cancer biotech Merus Genmab continues its shift from out-licensing drugs to developing its own drugs with an $8bn deal to buy Merus and its head and neck cancer therapy.
News Verona shareholders back $10bn MSD takeover MSD has moved a step closer to completing its acquisition of Verona Pharma, after a vote in favour of the transaction by the UK firm's shareholders.
News After internal setbacks, Pfizer buys obesity player Metsera Pfizer's answer to a string of disappointing projects in obesity R&D? Bolt on a promising pipeline from another developer.
News Biogen buys CNS delivery specialist Alcyone Therapeutics Biogen buys Alcyone, bringing a partnered technology for delivery of antisense drugs into the central nervous system in-house.
News Roche poised to buy MASH drug developer 89bio for $3.5bn Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its phase 3 candidate pegozafermin for MASH.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.